… mCRC, cetuximab plus irinotecan improved ORR more than cetuximab monotherapy in a …
(OS) between cetuximab plus irinotecan and cetuximab monotherapy in oxaliplatin-refractory …

… the head and neck, as is cetuximab monotherapy. When cetuximab is added to cisplatin
monotherapy in … squamous cell carcinoma of the head and neck, the objective response rate is …

… In recurrent/metastatic (R/M) HNSCC, we had to choose between monotherapy and
polychemotherapy until the results from the EXTREME trial. The addition of cetuximab to first-line …

… to investigate the efficacy of cetuximab as monotherapy in pts with … Cetuximab was given at
an initial dose of 400 mg/m 2 , … switch to the combination of cetuximab with the same platinum …

… cetuximab monotherapy or cetuximab in combination with cisplatin or carboplatin. The
principles of the study designs and their key inclusion and exclusion criteria are presented in …

… treated with cetuximab monotherapy to 125 … cetuximab monotherapy in the available
retrospective series. Both the MKSCC study and this study administered cetuximab monotherapy to …

… Cetuximab is also active as monotherapy in patients whose cancer has progressed on … on
cetuximab monotherapy in this trial were given the option to receive cetuximab and cisplatin; …

… FDA approved the indication of cetuximab monotherapy in patients with recurrent … cetuximab.
The results from the EXTREME trial (and from other studies of cetuximab in head and neck …

… Cetuximab monotherapy is also approved in the USA for the treatment of recurrent and/or …
study comparing cetuximab monotherapy with other chemotherapeutic agents in this setting. …

… Mechanisms of resistance to cetuximab in HNSCC are poorly understood. … cetuximab
therapy, we recently conducted a prospective clinical trial of neoadjuvant cetuximab monotherapy (…